Genscript Biotech Corporation Cash Flow Quality Index
Genscript Biotech Corporation cash flow quality index. Genscript Biotech Corporation (G51) has a Cash Flow Quality Index of 0.03x as of December 2024. Operating cash flow of €75.65 Million is below net income of €2.96 Billion, suggesting accrual-heavy earnings not yet converted to cash. Explore debt repayment capacity of Genscript Biotech Corporation to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Genscript Biotech Corporation (2016–2024)
Cash flow quality index of Genscript Biotech Corporation from 2016 to 2024. Historical Cash Flow Quality Index for Genscript Biotech Corporation across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. See G51 equity financing ratio to measure how much of total assets are equity-financed.
Genscript Biotech Corporation Cash Flow Quality Index by Year (2016–2024)
Genscript Biotech Corporation cash flow quality index by year from 2016 to 2024. Year-by-year earnings quality comparison for Genscript Biotech Corporation. For the full cash flow conversion analysis, see cash efficiency ratio of Genscript Biotech Corporation.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 0.03x | €75.65 Million | €2.96 Billion | ▼ -99.8% |
| 2018 | 14.50x | €307.66 Million | €21.22 Million | ▲ +1672.8% |
| 2017 | 0.82x | €21.37 Million | €26.12 Million | ▼ -35.7% |
| 2016 | 1.27x | €33.27 Million | €26.17 Million | — |